A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
在 Lucent-2 维持治疗试验中，Mirikizumab 对中重度活动性溃疡性结肠炎患者持续控制症状的疗效
期刊:Analytical and Bioanalytical Chemistry
影响因子:3.8
doi:10.1007/s00216-006-0883-6
Radjenovic, Jelena; Petrovic, Mira; Barceló, Damiá; Anand, R; Turolla, A; Chinellato, G; Giuliani, R; Sansi, F; Hartman, R; Anand, R; Turolla, A; Chinellato, G; Giuliani, R; Sansi, F; Hartman, R; Good, Steven S; Moussa, Adel; Zhou, Xiao-Jian; Sommadossi, Jean-Pierre; Pietropaolo, Keith; Ferdyan, Nicky; Papazyan, Romeo; Walsh, Dana; Klein, Sarah; Qi, Steve; Blount, Ken; Srinivasan, Karthik; Fuchs, Bryan; Dignass, A; Danese, S; Matsuoka, K; Ferrante, M; Long, M; Redondo, I; Gibble, T H; Moses, R; Li, X; Morris, N; Milch, C; Abreu, M; Jones, J
